PubMed Health⌕ Search

Biomedical subjects

M H Rogers

Publications and source records attributed to M H Rogers.

2 recordsLinked to original sources
PubMed2001

Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency.

OBJECTIVE: The objective was to evaluate the cognitive, behavioral, and neurodevelopmental function in patients with adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) and to compare the findings with those of a case control group of patients without ADA-SCID. STUDY DESIGN: Case-matched pairs of patients with ADA-SCID (n = 11) and patients without ADA-SCID who had undergone bone marrow transplantation were recruited. Subjects were assessed by age-appropriate standard tests of intelligence, behavior, and neurodevelopment. RESULTS: Cognitive ability was not significantly different between the 2 groups, but patients with ADA-SCID showed a significant inverse correlation between deoxyadenosinetrisphosphate levels at diagnosis and IQ (P =.048). Behavioral assessment showed that patients with ADA-SCID functioned in the pathologic range on all domains, whereas mean scores for the control group were within normal limits. Behavioral impairment in patients with ADA-SCID also showed a significant positive correlation with age (P =.026). CONCLUSIONS: Cognitive function in ADA deficiency is adversely affected by the severity of metabolic derangement at the time of diagnosis. In addition, patients with ADA-SCID have significant behavioral abnormalities after transplantation. These defects are not due to the transplant procedure but reflect the systemic nature of ADA deficiency. These findings have important implications for future medical and nonmedical management strategies.

Adenosine Deaminase↗
PubMed1977

Changes in primary process expression in hospitalized schizophrenics treated with phenothiazines: two projective tasks compared.

It was hypothesized that primary process expression on Gottschalk's Five Minute Verbalization Task (FMV) would be more representative of clinical status in schizophrenia than primary process expression on the Rorschach. Ss were 21 males and 15 females, ages 19-41 years, newly admitted to the hospital and treated with phenothiazines. The FMV was administered at predrug, five weeks, and 13 weeks, and the Rorschach at predrug and five weeks. Primary process scoring was according to the Holt system. Clinical improvement was measured by the Lorr IMPS and the Burdock Ward Behavior Scale. Over time, Ss produced less primary process on the FMV (p less than .001), while on the Rorschach scores did not change significantly. The scores on the FMV but not on the Rorschach paralleled some measures of clinical improvement (p less than .05). In a factor analysis, scores on the FMV and Rorschach were related to specific but different symptoms. It was concluded that the FMV was more effective in determining clinical improvement, while the Rorschach was perhaps more valuable in assessing the nature of the primary process thinking.

Adult↗